Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Melki

Showing results (51-60 of 102) with videos related to

Pageof 11
Sort By:
Seminars in Arthritis and Rheumatism|November 7, 2018
Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritisBrigitte Bader-Meunier, Roman Krzysiek, Irène Lemelle, et al.
Rheumatology (Oxford, England)|January 24, 2020
Inhibition of IFNα secretion in cells from patients with juvenile dermatomyositis under TBK1 inhibitor treatment revealed by single-molecular assay technologyCyril Gitiaux, Vincent Bondet, Nassima Bekaddour, et al.
Rheumatology (Oxford, England)|February 24, 2018
Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositisJessie Aouizerate, Marie De Antonio, Brigitte Bader-Meunier, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 14, 2020
From Diagnosis to Prognosis: Revisiting the Meaning of Muscle ISG15 Overexpression in Juvenile Inflammatory MyopathiesCyrielle Hou, Chloé Durrleman, Baptiste Periou, et al.
Rheumatology (Oxford, England)|March 18, 2024
TIF1-gamma IgG2 isotype is not associated with malignancy in juvenile dermatomyositis patientsHuong D Nguyen, Fabienne Jouen, Benoit Déchelotte, et al.
La Revue De Medecine Interne|June 21, 2025
French protocol for the diagnosis and management of juvenile idiopathic arthritis including pediatric-onset Still's diseasePierre Quartier, Alexandre Belot, Sylvain Breton, et al.
Musculoskeletal Care|March 10, 2023
Factors associated with poor prognosis of hip arthritis in juvenile idiopathic arthritis: Data from the JIR cohortWafa Hamdi, Hanene Ferjani, Raffaella Carlomagno, et al.
The Lancet. Child & Adolescent Health|July 6, 2020
Emergence of Kawasaki disease related to SARS-CoV-2 infection in an epicentre of the French COVID-19 epidemic: a time-series analysisNaim Ouldali, Marie Pouletty, Patricia Mariani, et al.
Pediatric Research|June 11, 2026
Type I interferon signature does not correlate with disease activity in Blau syndromeBenjamin Fournier, Héloïse Reumaux, Isabelle Melki, et al.
Rheumatology (Oxford, England)|February 12, 2021
JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective studyTom Le Voyer, Cyril Gitiaux, François-Jérôme Authier, et al.
Pageof 11

Showing results (51-60 of 102) with videos related to

Sort By:
Pageof 11
Seminars in Arthritis and Rheumatism|November 7, 2018
Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritisBrigitte Bader-Meunier, Roman Krzysiek, Irène Lemelle, et al.
Rheumatology (Oxford, England)|January 24, 2020
Inhibition of IFNα secretion in cells from patients with juvenile dermatomyositis under TBK1 inhibitor treatment revealed by single-molecular assay technologyCyril Gitiaux, Vincent Bondet, Nassima Bekaddour, et al.
Rheumatology (Oxford, England)|February 24, 2018
Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositisJessie Aouizerate, Marie De Antonio, Brigitte Bader-Meunier, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 14, 2020
From Diagnosis to Prognosis: Revisiting the Meaning of Muscle ISG15 Overexpression in Juvenile Inflammatory MyopathiesCyrielle Hou, Chloé Durrleman, Baptiste Periou, et al.
Rheumatology (Oxford, England)|March 18, 2024
TIF1-gamma IgG2 isotype is not associated with malignancy in juvenile dermatomyositis patientsHuong D Nguyen, Fabienne Jouen, Benoit Déchelotte, et al.
La Revue De Medecine Interne|June 21, 2025
French protocol for the diagnosis and management of juvenile idiopathic arthritis including pediatric-onset Still's diseasePierre Quartier, Alexandre Belot, Sylvain Breton, et al.
Musculoskeletal Care|March 10, 2023
Factors associated with poor prognosis of hip arthritis in juvenile idiopathic arthritis: Data from the JIR cohortWafa Hamdi, Hanene Ferjani, Raffaella Carlomagno, et al.
The Lancet. Child & Adolescent Health|July 6, 2020
Emergence of Kawasaki disease related to SARS-CoV-2 infection in an epicentre of the French COVID-19 epidemic: a time-series analysisNaim Ouldali, Marie Pouletty, Patricia Mariani, et al.
Pediatric Research|June 11, 2026
Type I interferon signature does not correlate with disease activity in Blau syndromeBenjamin Fournier, Héloïse Reumaux, Isabelle Melki, et al.
Rheumatology (Oxford, England)|February 12, 2021
JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective studyTom Le Voyer, Cyril Gitiaux, François-Jérôme Authier, et al.
Pageof 11